Validating discovery in literature-based discovery

Journal of Biomedical Informatics

Volumn 40, Issue 4, 2007, Pages 448-450

  Kostoff, Ronald N ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; ENDOCANNABINOID;

KNOWLEDGE; LETTER; MIGRAINE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCIENTIFIC LITERATURE; VALIDATION PROCESS;

ABSTRACTING AND INDEXING; ALGORITHMS; ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; DATABASE MANAGEMENT SYSTEMS; DATABASES, BIBLIOGRAPHIC; HUMANS; MEDICAL SUBJECT HEADINGS; MIGRAINE DISORDERS; MODELS, STATISTICAL; NATURAL LANGUAGE PROCESSING; PATTERN RECOGNITION, AUTOMATED; PUBMED; SCHIZOPHRENIA; SOFTWARE;

EID: 34547508214     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2007.05.001     Document Type: Letter

References (13)

1. Yetisgen-Yildiz M., and Pratt W. Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Inform 39 6 (2006) 600-611
2. Pazos M.R., Nunez E., Benito C., Tolon R.M., and Romero J. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci 75 16 (2004) 1907-1915
3. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23 35 (2003) 11136-11141 This article is referenced in Ref. [2]
4. Milton N.G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 332 2 (2002) 127-130
5. Fernandez-Ruiz J., Lastres-Becker I., Cabranes A., Gonzalez S., and Ramos J.A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66 2-3 (2002) 257-267
6. Lagalwar S., Bordayo E.Z., Hoffmann K.L., Fawcett J.R., and Frey II W.H. Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 13 1-2 (1999) 55-61
7. Healey P., Rothman H., and Hoch P.K. An experiment in science mapping for research planning. Res Policy 15 5 (1986) 233-251
8. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80 3 (2002) 448-456
9. Sang C.N., Ramadan N.M., Chappell A.S., Freitag F.G., Smith T.R., Silberstein S.D., and Tepper S.J. A double-blind, placebo-controlled study to investigate the efficacy and tolerability of 1.2 mg/kg intravenous LY293558 versus 6 mg subcutaneous sumatriptan versus placebo in patients with an acute migraine attack. Neurology 56 8 (2001) A218 [Suppl. 3]
10. Mitsikostas D.D., Sanchez del Rio M., Waeber C., Huang Z., Cutrer F.M., and Moskowitz M.A. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 127 3 (1999) 623-630
11. Mitsikostas D.D., and Sanchez del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Rev 35 1 (2001) 20-35
12. Ramadan N.M. The link between glutamate and migraine. CNS Spectr 8 6 (2003) 446-449
13. Beck V, Rimland B. Method of using secretin for treating autism. United States Patent 6,197,746, March 6; 2001.